靶向癌症中的神经细胞黏附分子

Targeting the neural cell adhesion molecule in cancer.

作者信息

Jensen Markus, Berthold Frank

机构信息

Department of Paediatric Oncology and Haematology, University of Cologne, Kerpener Strasse 62, 50924, Cologne, Germany.

出版信息

Cancer Lett. 2007 Dec 8;258(1):9-21. doi: 10.1016/j.canlet.2007.09.004. Epub 2007 Oct 18.

DOI:10.1016/j.canlet.2007.09.004

PMID:17949897

Abstract

NCAM is a tumour associated antigen expressed on small cell lung cancer, neuroblastoma, rhabdomyosarkoma, brain tumours, multiple myelomas and acute myeloid leukaemia. Constant and strong expression of NCAM is a prerequisite for the development of antibody-based immunotherapies. From the spectrum of existing anti-NCAM compounds, radioimmunoconjugates and immunotoxins represent the clinically most advanced and successful strategies. Here we provide an overview of the evolving field of anti-NCAM immunotherapy for cancer and discuss its indications and limitations.

摘要

神经细胞黏附分子（NCAM）是一种肿瘤相关抗原，在小细胞肺癌、神经母细胞瘤、横纹肌肉瘤、脑肿瘤、多发性骨髓瘤和急性髓细胞白血病中表达。NCAM持续且强烈的表达是基于抗体的免疫疗法发展的先决条件。从现有的抗NCAM化合物谱来看，放射免疫缀合物和免疫毒素代表了临床上最先进且成功的策略。在此，我们概述了癌症抗NCAM免疫疗法这一不断发展的领域，并讨论其适应证和局限性。